Editors' Pick Cost analysis of glatiramer acetate versus interferon-β for relapsing-remitting multiple sclerosis in patients with spasticity: the Escala study. Sánchez-de la Rosa R, García-Bujalance L, Meca-Lallana J Health Econ Rev. 2015 Dec; 5(1):30. Epub 2015 Oct 16. PMID: 26475277. Abstract CommentRecommendBookmarkWatch